13.06 14:31 | dpa-AFX: AbbVie To Receive License From FutureGen To Develop, Commercialize FG-M701 |
13.06 14:02 | dpa-AFX: *ABBVIE AND FUTUREGEN STRIKE $1.71 BLN DEAL TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
13.06 14:00 | dpa-AFX: *ABBVIE, FUTUREGEN TO DEVELOP NEXT-GENERATION THERAPY FOR INFLAMMATORY BOWEL DISEASE |
12.06 15:02 | dpa-AFX: AbbVie To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:00 AM ET |
06.06 15:34 | dpa-AFX: AbbVie Reports Positive Results From Phase 2 PICCOLO Trial Of Mirvetuximab Soravtansine In PSOC |
06.06 14:47 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL OF MIRVETUXIMAB SORAVTANSINE IN OVARIAN CANCER |
05.06 15:02 | dpa-AFX: *ABBVIE SAYS FIRST PATIENT TREATED WITH INVESTIGATIONAL ABBV-383 IN CERVINO PHASE 3 STUDY |
05.06 06:32 | dpa-AFX: *HSBC HEBT ABBVIE AUF 'BUY' - ZIEL 185 USD |
05.06 06:32 | dpa-AFX: *HSBC RAISES ABBVIE TO 'BUY' - PRICE TARGET 185 USD |
04.06 15:00 | dpa-AFX: AbbVie Says New Weight-based Oral Solution RINVOQ LQ Now Available As Option For Pediatric Patients |
04.06 14:42 | dpa-AFX: *ABBV : RINVOQ AVAILABLE FOR PEDIATRIC PATIENTS WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS &PSORIATIC ARTHRITIS |
31.05 08:45 | dpa-AFX: AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis |
31.05 08:24 | dpa-AFX: *ABBVIE'S RISANKIZUMAB RECEIVES POSITIVE CHMP OPINION FOR TREATMENT OF ACTIVE ULCERATIVE COLITIS |
28.05 14:04 | dpa-AFX: *ABBVIE SHOWCASES ROBUST SOLID TUMOR PIPELINE AT ASCO 2024, WITH NEW DATA FROM ADC PLATFORM |
23.05 22:06 | dpa-AFX: *ABBVIE COMPLETES ACQUISITION OF LANDOS BIOPHARMA |
13.05 15:17 | dpa-AFX: AbbVie To Collaborate With Gilgamesh To Develop Next-Gen Psychiatric Therapies |
13.05 14:44 | dpa-AFX: *ABBVIE TO PAY GILGAMESH $65 MLN UPFRONT FOR PSYCHIATRIC THERAPIES, POTENTIAL $1.95 BLN IN OPTION FEES, AND OTHERS |
13.05 14:42 | dpa-AFX: *ABBVIE, GILGAMESH COLLABORATE TO DEVELOP NEXT-GENERATION THERAPIES FOR PSYCHIATRIC DISORDERS |
08.05 15:37 | dpa-AFX: AbbVie's Qulipta Gets Health Canada Approval For Chronic Migraine In Adults |
08.05 14:04 | dpa-AFX: *ABBVIE : HEALTH CANADA APPROVES QULIPTA FOR PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN ADULTS |
|